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ABSTRACT
Background. Anemia at hemodialysis (HD) initiation is common. Correcting low hemoglobin (Hgb) before HD initiation may
improve survival by avoiding potential harms of chronic anemia, high doses of erythropoiesis-stimulating agents (ESAs)
and intravenous (IV) iron in the early HD period, and/or rapid Hgb rise.
Methods. We included 4604 incident HD patients from 21 countries in the Dialysis Outcomes and Practice Patterns Study
Phases 4–5 (2009–15). Because low Hgb at HD start may reflect comorbidity or ESA hyporesponse, we restricted our analysis
to the 80% of patients who achieved Hgb 10 g/dL 91–120 days after HD start (Month 4).
Results. About 53% of these patients had Hgb <10 g/dL in Month 1 (<30 days after HD start); they were younger with a
similar comorbidity profile (versus Hgb 10 g/dL). Month 1 Hgb was associated with first-year HD mortality (adjusted hazard
ratio for 1 g/dL higher Hgb was 0.89; 95% confidence interval: 0.81–0.97), despite minimal differences in Month 4 Hgb.
Patients with lower Hgb in Month 1 received higher doses of ESA, but not IV iron, over the first 3 months of HD. Results were
consistent when excluding catheter users or adjusting for IV iron and ESA dose over the first 3 months.
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Conclusions. Even among patients with Hgb 10 g/dL 3 months later, anemia at HD initiation was common and associated
with elevated mortality. A more proactive approach to anemia management in advanced chronic kidney disease (CKD) may
thus improve survival on HD, though long-term prospective studies of non-dialysis CKD patients are needed.
Keywords: anemia, chronic kidney disease, hemodialysis, hemoglobin, mortality
INTRODUCTION
Most chronic kidney disease (CKD) patients suffer from anemia
due to deficiencies in iron and erythropoietin, often resulting in
fatigue, weakness and an increased risk of cardiovascular com-
plications [1, 2]. A substantial proportion of CKD patients reach
end-stage kidney disease (ESKD) with very low hemoglobin
(Hgb) levels [3]. The most likely causes include: (i) uremic intoxi-
cation inhibiting erythropoiesis; (ii) lack of pre-ESKD nephrology
care; (iii) lack of adequate anemia treatment, despite nephrolo-
gist care, including insufficient correction of iron deficiency, as
illustrated by low levels of serum ferritin or transferrin satura-
tion (TSAT); or (iv) lack of responsiveness to anemia treatment,
often due to poor general health or acute illness. Regular
treatments with intravenous (IV) iron and erythropoiesis-
stimulating agents (ESAs) are standard for thrice-weekly
incenter hemodialysis (HD) patients, but are more difficult to
carry out for non-HD CKD patients who receive care
intermittently.
ESA and IV iron therapies are effective in raising Hgb levels
and avoiding blood transfusions [4–7]. However, concerns re-
garding ESA toxicity emerged following a number of random-
ized clinical trials (RCTs) [8–11]. Studies have consistently
demonstrated harmful effects of administering large doses of
ESA to reach and maintain higher Hgb levels [12], resulting in
clinically acceptable Hgb targets that are now generally in the
range of 10–12 g/dL [1, 13–16]. The practice of starting anemia
therapy at 9.5–10.0 g/dL, based on results from the Time to
Reconsider Evidence for Anemia Treatment (TREAT) trial (glo-
merular filtration rate 20–60 mL/min/1.73 m2) [11], may not be
directly applicable to the dialysis transition period.
Furthermore, two recent studies showed conflicting results re-
garding whether there may be a benefit [17] or no benefit [18] to
starting dialysis therapy with a higher Hgb level. Controversy
also remains in identifying optimal strategies for iron supple-
mentation in non-dialysis CKD and ESKD [19–23]. In the non-
dialysis CKD setting, the efficacy of IV iron to raise or sustain
Hgb levels has been well-established, but most RCTs do not
have sufficient follow-up to evaluate long-term safety [24]. In
the HD setting, large cohort studies of IV iron and mortality
have yielded mixed results [25–30]. While the recently published
Proactive IV irOn Therapy in haemodiALysis patients (PIVOTAL)
RCT [31] demonstrated non-inferiority of a proactive high IV
iron dose strategy, results may not be generalizable to all
Dialysis Outcomes and Practice Patterns Study (DOPPS)
countries—especially not the USA, where average iron doses
and ferritin levels are greater than even the high IV iron dose
PIVOTAL arm [32].
ESA and IV iron doses among long-term HD patients have
likely been titrated based on individual patient responsiveness
to treatment, but doses in the early HD period may more likely
be driven by nephrologist practice patterns and regional guide-
lines [1, 13–15]. Some nephrologists may choose to administer
very high doses of ESA and/or large bolus doses of IV iron to
quickly achieve Hgb increases and avoid the symptoms and
potential consequences of severe anemia. However, ESA labels
warn that rapid Hgb increases may increase risk of adverse car-
diovascular events [33, 34]. It is also possible that patients who
start HD with low Hgb experience worse outcomes on HD irre-
spective of HD treatment strategy.
We hypothesize that management of anemia before the
start of dialysis improves survival after HD start by avoiding the
potential harms of chronic anemia, high doses of ESA and IV
iron in the early months of HD, and/or a rapid Hgb rise. To test
this hypothesis, we will investigate: (i) the association between
anemia at HD start and all-cause mortality through 1 year of HD
and (ii) mortality rates for different doses of IV iron and ESA
during the early dialysis period.
MATERIALS AND METHODS
Data source
The DOPPS is a large, international prospective cohort study of
patients aged 18 years treated with incenter HD in 21 coun-
tries. Maintenance HD patients were randomly selected from
national samples of dialysis facilities in each country; detailed
information is included in prior publications [35, 36] and at
http://www.dopps.org. Study approval and patient consent
were obtained as required by national and local ethics commit-
tee regulations. This analysis included DOPPS Phase 4 (2009–11)
and Phase 5 (2012–15) patients who enrolled in the DOPPS
within 30 days after initiating HD.
Variables
Information on age, sex, post-dialysis weight, body mass index
(BMI), comorbid conditions [diabetes, hypertension, congestive
heart failure (CHF), peripheral vascular disease (PVD) and can-
cer] and catheter use was abstracted from medical records at
DOPPS enrollment. Monthly data on medication prescriptions
(ESA and IV iron) were also abstracted from medical records. To
convert ESA doses to units of IV epoetin, we used conversion
factors of 250:1 for darbepoetin [37] 208:1 (250/1.2) for pegylated
epoetin-b [38] and 1.15:1 for subcutaneous injections [39].
Laboratory values (Hgb, TSAT, ferritin, albumin and phospho-
rus) are described as ‘Month 1’ when measured 0–30 days after
starting HD (first measurement recorded in DOPPS) and ‘Month
4’ when measured 91–120 days after starting HD.
Study design
In our primary analysis, we estimated the effect of Month 1 Hgb
on all-cause mortality from Months 4 to 12. We restricted our
analysis to patients with Hgb 10.0 g/dL in Month 4 to facilitate
a comparison of mortality rates between patients with similar
Hgb levels 4 months after HD initiation (Figure 1). This allows us
to investigate whether the hypothesized harm of starting HD
with low (versus higher) Hgb is sustained even after a rapid Hgb
increase into target range. While Hgb targets, specifically upper
targets, are controversial [16] and have varied over time and by
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region [1, 13–15], we chose a restriction of 10 g/dL at Month 4.
Patients with low Hgb at HD start due to severe comorbidity or a
lack of responsiveness to pre-ESKD anemia therapy are less
likely to experience an Hgb increase to 10 g/dL in the subse-
quent months; those with Hgb 10 g/dL after 4 months on HD
would have theoretically been able to start HD with a higher
Hgb, with active anemia management prior to starting HD. By
excluding patients poorly responsive to anemia treatment after
dialysis start, our study is thus designed to include an exposure
variable that should mostly reflect differences in pre-ESKD ane-
mia care. Among 5726 patients with Hgb measured in Month 4,
we excluded 1122 (20%) with Hgb <10 g/dL. The remaining 4604
patients were eligible for the primary analysis (Figure 2); 447
from DOPPS Phase 4 and 4157 from DOPPS Phase 5, when more
emphasis was placed on enrolling incident HD patients.
Statistical analysis
Cox regression was used to estimate the effect of Month 1 Hgb
on all-cause mortality, restricted to patients with Month 4 Hgb
10.0 g/dL. Left-truncated Cox models were used, with time on
dialysis as the time scale; time at risk started after the Hgb mea-
surement in Month 4 and ended at the time of death, 7 days af-
ter leaving the facility due to transfer or change in kidney
replacement therapy modality, loss to follow-up, end of study
phase or 1 year after initiating HD (whichever event occurred
first). Hgb was categorized to explore the functional form of as-
sociation with mortality. Cox models were stratified by DOPPS
phase and country, and by dialysis chain affiliation in the USA.
Within-facility clustering was accounted for by using robust
sandwich covariance estimators. Covariates selected for adjust-
ment included age, sex, BMI, history of five comorbidities (dia-
betes, hypertension, CHF, PVD and cancer), catheter use at
study enrollment, serum albumin and phosphorus in Months 1
and 4, and Hgb in Month 4.
We performed several sensitivity analyses to test the robust-
ness of the findings. First, we additionally adjusted for ESA and
IV iron doses over the first 3 months of HD to investigate the
role of these potential mediators on causal pathways between
low Hgb at HD initiation and mortality. Second, we used Hgb
measured in the month prior to initiating HD as the exposure
rather than Month 1 Hgb. Third, we excluded patients dialyzing
with a catheter at study enrollment as a proxy for minimal pre-
ESKD nephrology care. Fourth, we additionally adjusted for an
indicator of >1 month of pre-ESKD nephrology care in a subset
of 29% of patients for whom the data were available. Fifth, we
varied the Month 4 Hgb restriction from 10.0 to 10.5 and
11.0 g/dL, because some ESA hyporesponsive patients could be
treated to Hgb 10.0 g/dL, but not readily to higher Hgb levels.
Sixth, we excluded patients not receiving any ESA therapy dur-
ing the first 3 months of HD, an indicator of likely endogenous
erythropoietin production in most patients.
In a secondary analysis not restricted to Month 4 Hgb 10 g/
dL, we illustrated the distribution of ESA and IV iron doses over
the first 3 months of HD therapy by Month 1 Hgb, TSAT and fer-
ritin across three regions (Europe, Japan and USA). Countries
outside of these three regions were included in the mortality
models but were not shown in these descriptive analyses due to
small sample sizes. In this population, we also estimated the
effects of average ESA and IV iron doses administered over the
first 3 months of HD on all-cause mortality. Cox regression mod-
els were implemented as in the primary analysis, with addi-
tional adjustment for Hgb, TSAT and ferritin in Month 1, but
without adjustment for Month 4 Hgb, a potential mediator. We
repeated this analysis in a subgroup of patients with Hgb
<10.0 g/dL in Month 1 to better inform optimal treatment practi-
ces for patients who initiated HD with low Hgb.
We used multiple imputation, assuming data were missing
at random, to impute missing covariate values using the
Sequential Regression Multiple Imputation Method by IVEware
[40]. Results from 20 such imputed data sets were combined for
the final analysis using Rubin’s formula [41]. The proportion of
missing data was <10% for all covariates, with the exception of
Month 1 laboratory measures (ferritin 28%; TSAT 27%; albumin
16%; phosphorus 11%) and the five comorbidities (10–21%). All
analyses were conducted using SAS software, version 9.4 (SAS
Institute, Cary, NC, USA).
FIGURE 1: Illustration of study design and timing of data collection. Hgb values
in Month 1 were measured 0–30 days after starting HD. Hgb values in Month 4
were measured 91–120 days after starting HD. The primary exposure is Month 1
Hgb. The primary analysis was restricted to 4604 patients with Hgb 10 g/dL in
Month 4, with mortality follow-up beginning after Hgb measurement in
Month 4, and ending after 12 months on HD. A secondary analysis of ESA and IV
iron doses and mortality was restricted to 5959 patients with no Hgb restriction
in Month 4.
FIGURE 2: Flow diagram of patient selection with inclusion/exclusion criteria.
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RESULTS
Patient characteristics
Our primary analysis included 4604 patients with Hgb 10.0 g/
dL in Month 4 after starting HD. Among these patients, 53% had
Hgb <10.0 g/dL in Month 1, including 6% with Hgb <8.0 g/dL.
Also, 20% had Hgb 11.0 g/dL in Month 1, including 7% with Hgb
12.0 g/dL and 2% with Hgb 13.0 g/dL. The mean Hgb in Month
4 was between 11.3 and 11.6 g/dL across the five groups of
Month 1 Hgb (from <8.0 to 11.0 g/dL). Patients with lower Hgb
in Month 1 were younger, more likely to dialyze with a catheter
and had higher ESA doses over the subsequent 3 months, but
only marginally higher IV iron doses (Table 1). Patients with
lower Hgb in Month 1 also had lower TSAT, higher serum
ferritin and lower serum albumin in Month 1, but all of these
differences were minimized by Month 4. The prevalence of
comorbidities varied minimally by Month 1 Hgb.
Hgb and mortality
Among the 4604 patients, we observed 277 deaths and a mortal-
ity rate of 0.105/year during follow-up. Patients with lower
Month 1 Hgb—those who experienced a rapid Hgb increase to
10.0 g/dL during the subsequent 3 months—had higher mortal-
ity rates than patients who started HD with higher Hgb
(Table 2). Compared with Hgb 11.0 g/dL, the adjusted hazard
ratio (HR) [95% confidence interval (CI)] was 1.99 (1.18–3.38) for
Hgb <8.0 g/dL and ranged from 1.18 to 1.35 for Hgb 8.0–10.9 g/dL
(Table 2, Model 3). As a continuous variable, Month 1 Hgb was
inversely associated with mortality (adjusted HR for 1 g/dL
higher Hgb ¼ 0.89; 95% CI: 0.81–0.97; P for trend ¼ 0.01). In sensi-
tivity analyses, the HR for 1 g/dL higher Hgb was generally con-
sistent when: (i) adjusting for potential mediators, ESA and IV
iron doses over the subsequent 3 months (HR¼ 0.89); (ii) using
Hgb measured in the month prior to initiating HD as the expo-
sure (HR¼ 0.90); (iii) excluding catheter users (HR¼ 0.84); (iv)
adjusting for >1 month of pre-ESKD nephrology care (HR¼ 0.87);
(v) varying the Month 4 Hgb restriction of 10.0 to 10.5
(HR¼ 0.87) and to 11.0 (HR¼ 0.89) g/dL; and (vi) excluding
patients not treated with ESA during the first 3 months of HD
(HR¼ 0.89).
Description of ESA and IV iron dosing
We also studied 5959 patients who survived to Month 4 (to mea-
sure ESA and IV iron doses administered over the first 3 months
Table 1. Patient characteristics by Hgb in Month 1 after starting HD, restricted to patients with Hgb 10.0 g/dL in Month 4 after starting HD
Patient characteristic All
Hgb (g/dL) in Month 1 after HD start
<8.0 8.0–8.9 9.0–9.9 10.0–10.9 11.0
Patients, n (%) 4604 283 (6) 822 (18) 1260 (28) 1209 (27) 897 (20)
Baseline characteristics and treatments
Age (years) 64.1 6 14.5 59.2 6 16.1 62.7 6 14.9 64.4 6 14.7 65.1 6 14.2 64.9 6 13.7
Sex (% male) 60 56 60 57 60 66
Post-dialysis weight (kg) 80.4 6 22.8 75.9 6 22.9 78.3 6 22.1 80.7 6 23.3 80.6 6 21.3 81.8 6 23.5
BMI (kg/m2) 28.1 6 6.9 26.8 6 6.3 27.2 6 6.5 28.4 6 7.2 28.3 6 6.6 28.4 6 7.0
Catheter use (%) 59 65 63 60 59 51
Hemodiafiltration (%) 3 2 3 3 3 4
Single pool Kt/V 1.33 6 0.35 1.28 6 0.37 1.33 6 0.37 1.35 6 0.35 1.33 6 0.35 1.33 6 0.35
Laboratory values <30 days after starting HD
Hgb (g/dL) 9.9 6 1.3 7.4 6 0.5 8.5 6 0.3 9.5 6 0.3 10.4 6 0.3 11.8 6 0.8
TSAT (%) 20.5 6 9.8 18.9 6 9.3 19.4 6 10.1 20.2 6 9.5 20.4 6 9.4 22.6 6 10.2
Ferritin (ng/mL) 337 6 334 402 6 365 366 6 368 336 6 325 331 6 333 305 6 305
Serum albumin (g/dL) 3.4 6 0.5 3.1 6 0.5 3.3 6 0.6 3.4 6 0.5 3.5 6 0.5 3.6 6 0.5
Serum phosphorus (mg/dL) 4.7 6 1.5 5.0 6 2.0 4.7 6 1.5 4.6 6 1.4 4.6 6 1.4 4.8 6 1.5
Laboratory values 91–120 days after starting HD
Hgb (g/dL) 11.5 6 1.0 11.3 6 1.0 11.5 6 1.0 11.4 6 1.0 11.4 6 0.9 11.6 6 1.1
TSAT (%) 26.6 6 11.7 26.6 6 12.5 25.7 6 12.4 26.4 6 11.4 26.7 6 11.4 28.0 6 11.9
Ferritin (ng/mL) 428 6 377 388 6 361 402 6 352 439 6 398 454 6 372 424 6 398
Serum albumin (g/dL) 3.7 6 0.4 3.6 6 0.5 3.6 6 0.5 3.6 6 0.5 3.7 6 0.4 3.7 6 0.4
Serum phosphorus (mg/dL) 5.2 6 1.5 5.5 6 1.6 5.4 6 1.7 5.2 6 1.5 5.2 6 1.4 4.9 6 1.3
Anemia treatment during first 3 months of HD
ESA use (%, any during 3 months) 92 98 98 98 91 77
ESA dose (1000 U/week) 12.7 6 10.4 19.6 6 13.6 16.7 6 11.0 13.8 6 10.1 10.8 6 8.3 8.0 6 8.9
IV iron use (%, any during 3 months) 86 86 87 87 86 82
IV iron dose (mg/month) 416 6 292 445 6 308 449 6 301 428 6 286 412 6 281 364 6 291
Comorbid conditions (%)
Diabetes 62 60 61 63 63 59
Hypertension 87 87 88 85 88 88
CHF 27 25 25 30 27 26
PVD 16 16 14 18 16 17
Cancer (non-skin) 11 9 12 12 12 9
Mean 6 standard deviation or % shown; mean ESA and IV iron doses averaged >3 months and treat nonusers as 0 dose; note columns do not sum to the total due to
133 (3%) patients missing Month 1 Hgb data.
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of HD), but not restricting to patients with Hgb 10.0 g/dL in
Month 4, to illustrate the variation in dosing patterns. Patients
with lower Month 1 Hgb had greater ESA doses over the
subsequent 3 months, reflecting indication for the treatment
and/or pre-ESKD ESA hyporesponsiveness (Figure 3a). Patients
with lower Month 1 Hgb had greater IV iron doses over the
Table 2. HR of mortality for Hgb measured in Month 1 after starting HD, by level of covariate adjustment, among patients with Hgb 10.0 g/dL
in Month 4 after starting HD
Exposure N (%) Model 1 Model 2 Model 3
Hgb (g/dL) in Month 1 after HD start, categories
<8.0 283 (6) 1.81 (1.07–3.05) 2.10 (1.25–3.54) 1.99 (1.18–3.38)
8.0–8.9 822 (18) 1.23 (0.81–1.86) 1.30 (0.87–1.95) 1.23 (0.83–1.84)
9.0–9.9 1260 (28) 1.52 (1.06–2.18) 1.39 (0.96–2.01) 1.35 (0.93–1.95)
10.0–10.9 1209 (27) 1.28 (0.89–1.85) 1.26 (0.86–1.84) 1.18 (0.81–1.73)
11.0 897 (20) 1 (Ref.) 1 (Ref.) 1 (Ref.)
Hgb (g/dL) in Month 1 after HD start, continuous
Per 1 g/dL – 0.91 (0.83–0.99) 0.88 (0.81–0.97) 0.89 (0.81–0.97)
HR (95% CI) of all-cause mortality in left-truncated Cox model (vintage time scale) from Month 4 to Month 12 of HD; all Cox models stratified by DOPPS phase, country
and US dialysis chain affiliation; Model 1: unadjusted; Model 2: adjusted for age, sex, BMI, five comorbidities (diabetes, hypertension, CHF, PVD and cancer) and catheter
use; Model 3: further adjusted for serum albumin and phosphorus in Months 1 and 4, and Hgb in Month 4.
FIGURE 3: Distribution of (a) ESA dose and (b) IV iron dose administered over the first 3 months of HD therapy, by region and Hgb measured during the first month of
HD. In contrast to primary analysis, these data were not restricted to patients with Hgb 10 g/dL in Month 4 after starting HD. Europe: Belgium, France, Germany, Italy,
Spain, Sweden and UK. Data from other regions (Canada, Australia, New Zealand, China, Russia, Turkey and Gulf Cooperation Council) were suppressed in this figure
due to small sample sizes, but were included in all other analyses.
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subsequent 3 months in Europe, but not in the USA, where a
median dose of 450–500 mg/month was observed regardless of
Hgb level (Figure 3b). IV iron doses in the first 3 months of HD
were higher among patients initiating HD with lower TSAT and
lower ferritin in all regions (Supplementary data, Figure S1).
However, relatively high IV iron doses were still observed
among many patients with ferritin levels 800 ng/mL. Overall,
ESA and IV iron doses in the first 3 months of HD were highest
in the USA, followed by Europe, and lowest in Japan across all
strata.
Anemia treatment and mortality
Among this population of 5959 patients who survived to Month
4, 92% were prescribed an ESA, and 83% were prescribed IV iron
at some point during the first 3 months on HD. The associations
of both ESA and IV iron doses over the first 3 months of HD on
all-cause mortality from Month 4 to Month 12 are shown in
Table 3. We observed elevated mortality at only very high ESA
doses; the adjusted HR (95% CI) was 1.43 (1.02–2.01) for >25 000
(12% of patients) versus 5000–10 000 units/week. In a subgroup
analysis of 3378 patients with Month 1 Hgb <10.0 g/dL, the pat-
tern was similar. The adjusted association between IV iron dose
and mortality was U-shaped, with the lowest mortality rate ob-
served for patients receiving 200–399 mg/month in both the
whole sample and subgroup with Month 1 Hgb <10.0 g/dL
(Table 3).
DISCUSSION
Among patients with Hgb levels 10.0 g/dL in Month 4 of HD,
53% of patients had Hgb <10.0 g/dL in Month 1 after HD initia-
tion, and lower Hgb in Month 1 of HD was associated with a
higher mortality rate in Months 4–12. While we expected to ob-
serve a greater mortality rate for patients who initiated HD with
low Hgb, this elevated rate was still observed among patients
achieving Hgb 10.0 g/dL in the early HD period. In secondary
analyses not restricted to Hgb 10.0 g/dL in Month 4 of HD, we
found a U-shaped association between IV iron dose over the
first 3 months of HD and mortality, and elevated mortality for
patients receiving the largest doses of ESA (>25 000 U/week).
Our primary result (Table 2, Model 3) is consistent with our
hypothesis that management of anemia before the start of dial-
ysis improves survival after HD start, although there are many
possible explanations for these findings. One potential explana-
tion is that intense anemia treatment and/or a rapid Hgb rise in
the early HD period may be responsible for the elevated mortal-
ity rate. Patients who started HD with the lowest Hgb levels re-
ceived the largest ESA doses over the first 3 months of HD.
However, additional adjustment for ESA and IV iron doses (po-
tential mediators) had minimal impact on the association be-
tween Hgb at HD initiation and mortality, thus making this
explanation unlikely, though we did not conduct a formal medi-
ation analysis [42]. Another possibility is that anemia treatment
prior to ESKD has long-term benefits compared with initiating
anemia therapy after HD start. Among patients with Hgb
10.0 g/dL in Month 4 of HD, mean Hgb levels in Month 4 were
similar for patients who initiated HD with Hgb 11.0 (11.6 g/dL)
versus Hgb <8.0 (11.3 g/dL) g/dL. The subsequent mortality rate
was twice as high for patients who started HD with Hgb <8.0
versus 11.0 g/dL, despite also having a similar comorbidity pro-
file (Table 1). This striking difference in mortality may point to a
lingering effect of untreated anemia in CKD. We also found an
18–35% greater mortality rate between Hgb 8.0–10.9 and 11.0 g/
dL, though surprisingly minimal difference within the range of
8.0–10.9 g/dL. It is possible that a ‘step function’ exists, with
low-, medium- and high-risk groups, though our study is not
powered to detect the exact Hgb cutpoints. In addition, a non-
causal explanation is that the association may be biased due to
residual confounding, possibly because patients with higher
Hgb at HD start adhered more to prescribed treatments and rec-
ommendations and/or received better overall quality of care be-
fore HD initiation. We adjusted for catheter use at study
enrollment as a proxy for this latter potential confounder, and
also excluded catheter users in a sensitivity analysis.
Table 3. HR of mortality for ESA and IV iron doses over the first 3 months of HD without restricting to patients with Hgb 10 g/dL in Month 4,
overall and among a subset of patients with Hgb <10.0 g/dL in Month 1 of HD
All HD patients
Restricted to subset with Hgb <10.0 g/dL





(95% CI) (95% CI)
Average ESA dose (units/week) over first 3 months on HD
None 479 (8) 0.94 (0.59–1.51) 103 (3) 0.63 (0.22–1.82)
<5K 711 (12) 0.84 (0.54–1.29) 253 (8) 0.56 (0.25–1.27)
5K–10K 1543 (26) 1 (Ref.) 836 (25) 1 (Ref.)
10K–15K 1203 (21) 0.89 (0.64–1.24) 773 (23) 0.85 (0.56–1.27)
15K–25K 1223 (21) 0.97 (0.71–1.33) 818 (25) 0.80 (0.53–1.20)
>25K 699 (12) 1.43 (1.02–2.01) 537 (16) 1.54 (1.01–2.36)
Average IV iron dose (mg/month) over first 3 months on HD
None 1008 (17) 1.50 (1.05–2.15) 549 (17) 1.74 (1.08–2.79)
<200 741 (13) 1.08 (0.72–1.62) 407 (12) 1.25 (0.74–2.10)
200–399 1157 (20) 1 (Ref.) 605 (18) 1 (Ref.)
400–599 1359 (23) 1.11 (0.78–1.57) 783 (24) 1.39 (0.88–2.18)
600 1604 (27) 1.24 (0.87–1.76) 975 (29) 1.29 (0.80–2.07)
HR (95% CI) of all-cause mortality in left-truncated Cox model (vintage time scale) from Month 4 to Month 12 of HD; Cox models stratified by DOPPS phase, country and
US dialysis chain affiliation. Adjustments: age, sex, BMI, five comorbidities (diabetes, hypertension, CHF, PVD and cancer), catheter use, serum albumin and phospho-
rus in Month 1 and Month 4, Hgb, TSAT and ferritin in Month 1. Note this analysis was not restricted to patients with Hgb 10 g/dL in Month 4.
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The relation between anemia management during the tran-
sition period to ESKD and post-dialysis outcomes is challenging
to assess and often requires an innovative study design. Mc
Causland et al. [18] performed a post hoc follow-up analysis of
TREAT among the subset (only 15%) of randomized patients
who reached ESKD [11]. Mean Hgb at dialysis start was higher in
the darbepoetin intervention (11.3 g/dL) versus the control
(9.5 g/dL) group, but no all-cause mortality benefit (HR¼ 1.16;
95% CI: 0.69–1.93) was observed from HD start (when anemia
therapy switched from protocol-driven to physician-driven)
through 6 months; differences with our study may be explained
by the study design and/or selection criteria. An increased
stroke rate was observed in the intervention group, although
paradoxically, it is likely ESA doses were much higher (by indi-
cation) during the at-risk period in the control group. The
authors concluded that there is no apparent benefit from start-
ing dialysis therapy with a higher Hgb level, but acknowledged
other factors (e.g. avoiding transfusions) should help inform
whether to treat mild-to-moderate anemia with ESA in CKD
patients preparing for dialysis. A recent study by Wetmore et al.
[17], using United States Renal Data System (USRDS) data, in
contrast to Mc Causland et al. [18], drew similar conclusions as
our study when analyzing US Medicare patients >66 years old at
dialysis initiation. The 1-year mortality rate was slightly lower
(HR¼ 0.88) among patients treated with ESA prior to dialysis
start and who maintained Hgb 9.0 g/dL during the 3 months
before and after dialysis start versus patients with Hgb <9.0 g/dL
before dialysis start who then received ESA after HD start and
experienced an Hgb increase to 9.0 g/dL. It is encouraging that
the current DOPPS study achieved similar findings to the USRDS
study while using a different data source (international sample
with no age restriction) and a different analytical approach to
address the question of interest.
Results from large observational studies [43, 44] are consis-
tent with our finding that patients receiving the highest ESA
doses in the early HD period had worse survival. Following
patients soon after HD initiation may better capture dosing pat-
terns (practice preferences) before patients transition to a more
individualized steady-state dosing protocol, at which point ob-
served associations between ESA dose and mortality are more
likely attributable to confounding factors that drive ESA dose
requirements than a causal effect [45, 46].
While our main focus was on Hgb levels, we also investi-
gated IV iron dosing. IV iron dose over the first 3 months of HD
was generally greater in patients who initiated HD with low lev-
els of ferritin and TSAT, as expected. Patients starting HD with
lower (versus higher) Hgb received more IV iron in the next
3 months, but this pattern was not observed in the USA, where a
high median dose of 450–500 mg/month was observed regard-
less of Hgb at HD start. This may reflect the practice of bolus IV
iron dosing in many US facilities, where doses of at least 100 mg
are administered in consecutive HD sessions [47, 48]. Michels et
al. [49] found that a low-dose (versus bolus dose) IV iron strategy
in the early HD period may be beneficial by reducing ESA doses
and risk of mortality. While we did not assess specific dosing
patterns, we similarly observed a greater mortality rate at high
doses of IV iron that would generally characterize a bolus dos-
ing strategy, with the lowest mortality rate observed at 200–
399 mg/month. Our results were also consistent with Kuo et al.
[50] who demonstrated that a low-dose IV iron strategy was op-
timal for incident HD patients. The recent PIVOTAL trial ran-
domized patients to a proactive high IV iron dose (400 mg/
month IV iron; discontinue if ferritin >700 ng/mL or TSAT >40%)
or reactive low IV iron dose (100–400 mg/month IV iron;
discontinue if ferritin >200 ng/mL and TSAT >20%) and demon-
strated non-inferiority of the high IV iron dose strategy [31];
however, these ‘high’ doses were lower than the median dose of
450–500 mg/month we observed in the USA, and the upper ferri-
tin threshold of 700 ng/mL in the ‘proactive’ arm was lower than
the median serum ferritin levels observed in the USA [32].
Generalizability of these findings in the context of the high lev-
els of serum ferritin and IV iron dosing observed in the USA
remains an open question.
This analysis had some limitations. First, to address poten-
tial residual confounding due to better pre-ESKD care (unrelated
to anemia), we adjusted for catheter use at study enrollment, a
proxy for lack of pre-ESKD nephrology care. Regarding potential
residual confounding due to health status, it is reassuring that
the distribution of key risk factors (e.g. serum albumin at Month
4) and prevalence of comorbidities was similar by Hgb level at
HD initiation (Table 1). Second, we were unable to determine
history of anemia therapy—including usage or dosage—prior to
HD start, which would have helped inform the cause(s) of initi-
ating HD with low Hgb (e.g. lack or treatment or hyporespon-
siveness); this limitation prompted us to restrict to patients
with Hgb 10 g/dL in Month 4, excluding patients whose low
Month 1 Hgb was likely due to poor general health or ESA hypo-
responsiveness, thus using low Hgb at HD start as a proxy for
lack of pre-ESKD anemia treatment. Third, data on potentially
important variables were not available for a majority of
patients, including transfusions, C-reactive protein (not mea-
sured in North America) and residual kidney function. Finally,
our exposure variable was Hgb measured within 30 days after
initiating HD (median¼ 13 days), but Hgb could have changed in
the days immediately after starting HD. We thus performed a
sensitivity analysis in a subset of patients for which data were
available on Hgb levels immediately prior to starting HD.
This analysis also had some key strengths. We considered
mortality as the primary outcome rather than a surrogate out-
come, such as change in Hgb, which is often used in smaller
RCTs with short follow-up to demonstrate effectiveness, but not
safety, of pre-ESKD anemia therapies. Furthermore, the large in-
ternational DOPPS sample reflected a wide range of anemia
management practices in the early HD period. In particular, we
observed that IV iron prescription patterns did not appear to be
driven by Hgb levels in the USA, where doses were very high in
the first 3 months of HD (median 450–500 mg/month).
In this study, we found that, even among patients who
achieved Hgb 10.0 g/dL within 4 months of starting HD, low
Hgb at HD initiation was common (53% had <10.0 g/dL) and was
associated with elevated mortality. Compared with Hgb 11.0 g/
dL at HD start, we observed a 2-fold greater mortality rate for
Hgb <8.0 g/dL and an 18–35% greater mortality rate for Hgb 8.0–
10.9 g/dL. A more proactive approach to anemia management in
advanced CKD may thus improve first-year survival on HD,
though long-term prospective studies examining anemia treat-
ments and adverse events starting in the nondialysis CKD set-
ting are needed.
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